Cancer Institute A national cancer institute
designated cancer center

Michael F. Clarke, M.D.

Publication Details

  • c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle.

    Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nuñez G, Clarke MF. Proc Natl Acad Sci U S A. 1994; 91 (13): 5878-82

    We have studied the ability of c-myc and bcl-2 oncogenes to modulate p53 function. Our studies show that coincident expression of human Bcl-2 protein with p53 prolongs survival of murine erythroleukemia cells. This effect was associated with a loss of the G1 specificity of p53-mediated cell cycle arrest. Furthermore, we found that the c-myc and bcl-2 genes cooperate to inhibit p53 functions. Coexpression of bcl-2 and c-myc can totally overcome p53-induced apoptosis and cell cycle arrest by altering the subcellular trafficking of p53 during the cell cycle: the p53 remains in the cytoplasm of the cotransfected cells during a critical period in G1. This finding suggests a mechanism by which normal hematopoietic progenitors can survive and proliferate despite p53 expression and by which the inappropriate expression of bcl-2 and c-myc can cooperate in transformation.

    PubMedID: 8016082

Stanford Medicine Resources:

Footer Links: